The procedure for MS is HSCT. It's erroneously called "transplant," as it actually is stem-cell rescue. The basic idea is to extract your own stem cells, kill of most (not all) of your existing immune system, and then re-infuse your stem cells to "reinstall" your immune system. Hopefully before you get an infection while you don't have any defenses.
This treatment has been shown to be effective for the most mild form of MS, Relapsing Remitting (RRMS), and only in the early stages of the disease. It's relatively risky, and if we were to do the procedure for everyone diagnosed with RRMS today, hundreds (if not thousands) of people would die from the treatment. Either from complications from the procedure, or from increased instances of cancer years down the road, since the poison part of the treatment is known to be carcinogenic.
Meanwhile, there is Rituximab, which is a monoclonal antibody targeting the CD20 protein that has had its patent recently expire. This means it can be manufactured as a generic. Clinical trials recently run in England have shown that not only is it extremely effective at controlling the disease in the most mild form (RRMS), but CD20-targeting monoclonal antibodies are the only drugs known to be in any (meaningful) way effective for the more serious forms of the disease, Secondary Progressive (SPMS) and Primary Progressive (PPMS).
Given the choice between HSCT or Rituximab, in terms of effectiveness, safety and cost, Rituximab wins as a treatment for MS, hands-down.
For those stuck in the United States, the FDA will let you get Ocrelizumab (Ocrevus), which is basically Rituximab tweaked enough so that Genentech could get patent protection for it. With that patent protection, they got the financial incentive to run it through the FDA approval process so they can now sell it to you for the bargain price of about $80,000 per year. It's just about as effective as Rituximab and maybe only a little more dangerous.